Familial multiple myeloma: Report on two families and discussion of screening options

Hereditary Cancer in Clinical Practice

Volumn 5, Issue 2, 2007, Pages 72-78

  Gerkes, Erica H ^a   De Jong, Mirjam M ^a   Sijmons, Rolf H ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Familial; Multiple myeloma; Screening

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FAMILIAL DISEASE; FAMILY HISTORY; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PARAPROTEINEMIA; PROTEIN ELECTROPHORESIS; RELATIVE; SHOULDER PAIN; URINE;

EID: 34447545765     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-5-2-72     Document Type: Article

References (31)

1. Munshi NC, Tricot G, Barlogi B. Plasma Cell Neoplasms. In: DeVita Jr. VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology; 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2001: 2465-2499.
2. Selby P, Gore M. Myeloma and Other Plasma Cell Malignancies. In Peckham M, Pinedo H. Veronesi U. Oxford Textbook of Oncology. Vol. 2. Oxford, Oxford University Press 1995: 1852-1878.
3. Association of Comprehensive Cancer Centres, The Netherlands. 2003.
4. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82: 323-341.
5. Grosbois B, Jego P, Attal M, Payen C, Rapp MJ, Fuzibet JG, Maigre M, Bataille R. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999; 105: 768-770.
6. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001; 93: 1479-1483.
7. Sobol H, Vey N, Sauvan R, Philip N, Noguchi T, Eisinger F. Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2002; 94: 461-462.
8. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 2004; 32: 246-261.
9. Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Isgur Bergsagel K, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 2005; 23: 685-893.
10. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006; 42: 1661-1670.
11. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095-3098.
12. Baris D, Silverman DT, Brown LM, Swanson GM, Hayes RB, Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Greenberg RS, Stewart PA. Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health 2004; 30: 215-222.
13. Lewis EB. Leukemia, multiple myeloma, and aplastic anemia in American radiologists. Science 1963; 142: 1492-1494.
14. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D. Multiple myeloma: A review of the epidemiologic literature. Int J Cancer 2007; 120 Suppl 12: 40-61.
15. Horwitz LJ, Levy RN, Rosner F. Multiple myeloma in three siblings. Arch Intern Med 1985; 145: 1449-1450.
16. Engelhardt M, Ihorst G, Behringer D, Finke J, Roth B. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica 2006; 91: 274-276.
17. Ogmundsdottir HM, Haraldsdottirm V, Johannesson GM, Olafsdottir G, Bjarnadottir K, Sigvaldason H, Tulinius H. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 2005; 90: 66-71.
18. Brown EE, Lan Q, Zheng T, Zhang Y, Wang SS, Hoar-Zahm S, Chanock SJ, Rothman N, Baris D. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007; 120: 2715-2722.
19. Higgins MJ, Fonseca R. Genetics of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 525-536.
20. Liebisch P, Dohner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 2006; 42: 1520-1529.
21. Hemminki K. Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2002; 94: 462-463.
22. Eriksson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 1992; 3: 63-67.
23. Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM, Schwartz AG, Schoenberg JB, Pottern LM, Fraumeni JF Jr. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999; 85: 2385-2390.
24. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004; 41: 801-807.
25. Dougherty SE, Pfeiffer RM, Mellemkjaer L, Hemminki K, Goldin LR. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14: 1245-1250.
26. rd ed. Cambridge, Cambridge University Press; 2007, 120-131.
27. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569.
28. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 54: 1362-1369.
29. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. UpToDate 2006: http://www.utdol.com/utd/index.do.
30. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-393.
31. Hussein MA. Multiple myeloma: most common end-organ damage and management. J Natl Compr Canc Netw 2007; 5: 170-178.